

ASX RELEASE

1 October 2021

## AMPLIA APPOINTS NEW CHIEF FINANCIAL OFFICER

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), today announced that it has appointed Mr Hamish George of Melbourne-based Bio101 to provide Chief Financial Officer services to the Company, effective 1 October 2021.

Mr Jeff Carter, who has been Chief Financial Officer for the Company for more than 8 years, is stepping down from the role. Jeff was part of the original team that managed the public listing of the Company on the Australian Stock Exchange in 2013. Dr John Lambert, CEO of Amplia Therapeutics commented: “I would like to thank Jeff for his exemplary service to Amplia and particularly for the support he has provided to me over the last 2 years. Jeff’s insights into the financial markets, compliance and his focus on good governance have been a great asset and we wish Jeff well in his other on-going CFO roles.”

This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

### For Further Information

Dr. John Lambert

CEO and Managing Director

[john@ampliatx.com](mailto:john@ampliatx.com)

[www.ampliatx.com](http://www.ampliatx.com)

### About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).